In contrast to BAY-D, BAY-I treatment led to significantly increased prostate cancer-associated CD45+ and CD8+ T cell numbers, and CD8+ T cell percentage in CD45+ cell without altering spleen associated CD45+ cell, CD4+ T cell and CD8+ T cell numbers (Fig. 2B, C; Supplementary Fig. 3A), so we decided to focus our current study on the effects of BAY-I on T cells. The gene discussed is CD4; the disease is prostate carcinoma.